Full-Time

Associate Regulatory Affairs CMC Director

Confirmed live in the last 24 hours

Exelixis

Exelixis

1,001-5,000 employees

Develops and commercializes cancer therapies

Compensation Overview

$158k - $224.5k/yr

+ Bonus + Sales-based Incentive Plan

Senior, Expert

King of Prussia, PA, USA + 1 more

More locations: Alameda, CA, USA

Category
Risk & Compliance
Legal & Compliance
Requirements
  • Bachelor’s degree in related discipline and a minimum of eleven years of related experience; or,
  • Master’s degree in related discipline and a minimum of nine years of related experience; or,
  • PhD degree in related discipline and a minimum of five years of related experience; or,
  • Equivalent combination of education and experience.
  • Develops and manages plans within established timelines and balances commitments to complete multiple activities and achieve results. Takes pride in delivering high quality work.
  • Applies wide knowledge of the regulatory framework and industry practices to develop innovative approaches and complete complex work.
  • Demonstrates clear and effective verbal and written communication. Provides timely and appropriate information updates. Speaks clearly and confidently in one-to-one situations and effectively presents information to groups of departmental colleagues.
  • Strong interpersonal skills and ability to accommodate differing views to actively support the development of an agreed upon resolution.
  • Manages effectively performing teams to achieve common objectives. Engages internal stakeholders to establish productive collaborative relationships.
  • Applies knowledge of organizational goals and objectives and demonstrates skill and insight in gathering, analyzing and applying key information to solve problems.
  • Leads self and others; acts with integrity and builds trust with colleagues to contribute to accomplishing team objectives.
Responsibilities
  • Coordinate CMC-related submissions to regulatory authorities and track progress of submission, review, and approval, including submissions across multiple countries and clinical studies. Help coordinate responses to questions. Ensure appropriate archiving of documentation.
  • Support cross-functional project teams on core Module 3 development, writing, and appropriate updates. Facilitate transition of core Module 3 documents to regional format (e.g., IMPD, QOS).
  • Prepare and review CMC related documentation (e.g., INDs, IMPDs, NDAs, BLAs) for compliance with regulatory guidance and as appropriate for the phase of development; may be required to provide relevant content or develop documents and templates, as necessary.
  • Track and manage regulatory actions associated with post-approval and development stage changes through completion.
  • Liaise internally with other members of the Regulatory Affairs department to coordinate CMC changes with other aspects of the development programs.
  • Ensure continued regulatory compliance through adherence to change control procedures and completion of regulatory impact assessments.
  • Monitor CMC regulations and guidance to assess relevant changes and implications to current and future development and commercial activities.
  • Contribute in the implementation of processes and procedures, including developing and authoring internal work instructions and company SOPs.
  • Work with cross-functional teams to identify and support continuous improvement opportunities for processes and systems.
  • Liaise internally with members of Exelixis’ functional departments.
  • Liaise externally with vendors, partners, and joint development collaborators.

Exelixis develops and commercializes medicines specifically for cancer treatment. The company creates therapies that target various biological pathways and are designed to be used in combination with other treatments, which helps to enhance their effectiveness and tolerability. Exelixis primarily focuses on patients with advanced cancers, such as renal cell carcinoma, and operates within the oncology sector. Their process involves extensive research, clinical trials, and obtaining regulatory approvals to introduce new drugs to the market. Unlike many competitors, Exelixis emphasizes a combination approach in its therapies, which can lead to better patient outcomes. The company's goal is to improve the quality of life for cancer patients and provide them with hope for remission through its drug development efforts.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

1994

Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic partnerships can expand Exelixis' pipeline and market reach.
  • AI-driven drug discovery accelerates identification of novel cancer targets for Exelixis.
  • Telemedicine improves patient monitoring, enhancing outcomes of Exelixis' therapies.

What critics are saying

  • Generic competition may reduce market share for CABOMETYX®.
  • Reliance on future drug approvals may not meet expectations.
  • Need for additional funding may indicate financial pressures.

What makes Exelixis unique

  • Exelixis focuses on combination regimens for advanced cancer treatment.
  • The company targets multiple pathways to create effective and durable cancer therapies.
  • Exelixis has a strong pipeline with four molecules in preclinical stages.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Employee Stock Purchase Plan

Company News

Medical Update Online
Mar 28th, 2025
Exelixis to present preclinical data for four pipeline molecules at AACR 2025

Exelixis to present preclinical data for four pipeline molecules at AACR 2025.

Defense World
Mar 9th, 2025
Proficio Capital Partners LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL)

Proficio Capital Partners LLC makes new investment in Exelixis, Inc. (NASDAQ:EXEL).

Stock Titan
Feb 13th, 2025
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

Exelixis to participate in the Citi 2025 Virtual Oncology Leadership Summit.

MarketBeat
Jan 7th, 2025
Range Financial Group LLC Invests $994,000 in Exelixis, Inc. (NASDAQ:EXEL)

Range Financial Group LLC invests $994,000 in Exelixis, Inc. (NASDAQ:EXEL).

Stock Titan
Jan 6th, 2025
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Exelixis to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.